<DOC>
	<DOCNO>NCT00721955</DOCNO>
	<brief_summary>Phase 3 safety efficacy study Staccato Loxapine treatment acute agitation bipolar 1 disorder patient .</brief_summary>
	<brief_title>StaccatoÂ® Loxapine Treatment Agitation Bipolar Disorder Patients</brief_title>
	<detailed_description>This in-clinic , multi-center , randomize , double-blind , placebo-controlled study 2 dose level Staccato Loxapine , 5 10 mg . Patients may receive 3 dos study drug 24-hour period , depend clinical status . The primary endpoint change baseline PANSS ( Positive Negative Symptom Scale ) Excited Component ( also know PEC ) score , perform 2 hour first dose .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<criteria>Male female adult patient bipolar 1 disorder acute agitation Agitation cause primarily acute intoxication History drug alcohol dependence Treatment benzodiazepines hypnotic within 4 hour prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bipolar 1 disorder ,</keyword>
	<keyword>agitation ,</keyword>
	<keyword>acute ,</keyword>
	<keyword>treatment</keyword>
</DOC>